OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals	588
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?	231
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	180
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	138
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	120
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers	105
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	99
May Infographic	94
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	90
In Memoriam Mahlon R. DeLong (1938–2024)	90
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model	89
	83
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials	78
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease	78
Movement Disorders: Volume 40, Number 6, June 2025	77
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease	74
Movement Disorders: Volume 40, Number 2, February 2025	73
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	67
John Michael Walshe (April 24, 1920–October 14, 2022)	66
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	66
Issue Information	66
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	65
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease	62
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia	62
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters	59

The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	59
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy	58
Biallelic Variants in SLC27A3 Cause a Complex Form of Neurodegeneration with Brain Iron Accumulation	57
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property	56
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease	55
Reply to: “Early Indian Age at Onset of Parkinson's: A Case for a Gene‐Environment Lens”	54
Re‐emergent Tremor in Parkinson's Disease: Evidence of Pathologic β and Prokinetic γ Activity	53
Friedreich's Ataxia in Colombia: A Population‐Based Study of Incidence and Socioeconomic Determinants	53
A CGG Repeat Expansion in CSNK1E Associated with Progressive Myoclonic Epilepsy with Incomplete Penetrance	50
Neurodevelopmental Disorder and Cortical Myoclonus in ZMYM2 Deficiency	50
Compound Heterozygous Structural Variants in Cases with Unsolved PRKN‐Associated Parkinson's Disease	50
Dystonia	49
AI, Technology, Telemedicine	49
Author Index	48
Patients with Allan‐Herndon‐Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment	47
Functional Movement Disorders and Drug‐Induced Movement Disorders	47
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease	47
Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy	46
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation	46
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and ¹⁸F‐Fluorodopa‐Positron Emission Tomography	46
	45
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease	44
Oligodendrocyte and Extracellular Matrix Contributions to Central Nervous System Motor Function: Implications for Dystonia	44
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease	42
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder	41
Thank you to Reviewers 2022	41
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”	41
Issue Information	41
Research Priorities on the Role of α‐Synuclein in Parkinson's Disease Pathogenesis	40
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease	40
Reply to: “An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis”	40
Lesion of the Subthalamic Nucleus Should Not be Labeled “Subthalamotomy”; A Plea for Anatomical Accuracy and Compliance with Historical Legacy	40
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search	40
Substantiating the Short Burst Duration in Cortical Myoclonus	40
Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double‐Blinded Evaluation	39
Genetic Determinants of Survival in Parkinson's Disease in the Asian Population	39
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine	38
Issue Information	38
Movement Disorders: Volume 37, Number 9, September 2022	38
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies	38
Movement Disorders: Volume 36, Number 11, November 2021	38
De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia	37
Effect of Public Interest in Magnetic Resonance Imaging–Guided Focused Ultrasound on Enrolment for Deep Brain Stimulation	37
Obituary for Jan O. Aasly (1950–2022)	37
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	37
	37
Plant‐Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank	37
The Lows of High Reward: Choking Under Pressure	37
Sex and Racial/Ethnic Differences in End‐of‐Life Care Preferences in Persons with Parkinson's Disease and Related Disorders	36
COVID‐19 Infection Enhances Susceptibility to Oxidative Stress–Induced Parkinsonism	36

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	36
Education, History, Disparities, Other Topics	36
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia	35
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review	35
Levodopa Disrupts Activity Patterns and Encoding of Movement in Striatal Cholinergic Interneurons of Behaving Mice	33
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review	33
Deciphering the Janus‐Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis	33
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis	33
The Self‐Administered Screening Questionnaire for Parkinson's Disease‐Associated Psychosis (SASPAP)	33
Comparison of Two α‐Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism	33
Low/High Multi‐Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease	33
Issue Information	32
Ethnic Differences in Dystonia Prevalence and Phenotype	32
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ‐009	32
Structural Alterations in the Gray Matter Volume in Rapid‐Onset Dystonia‐Parkinsonism	32
Prediction of Pathological Subthalamic Nucleus Beta Burst Occurrence in Parkinson's Disease	32
Free‐Water Imaging in Friedreich Ataxia Using Multi‐Compartment Models	31
Essential Tremor Suppression with a Novel Anti‐Tremor Orthosis: A Randomized Crossover Trial	31
August Infographic	31
Issue Information	31
Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease	30
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy	30
Parkinsonisms	29
Issue Information	29
February Infographic	29
Correction to “Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus”	29
Genetic Determined Iron Starvation Signature in Friedreich's Ataxia	29
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease	28
Teaching an Old Drug a New Trick for Dystonia	28
Secondary Paroxysmal Kinesigenic Dyskinesia with a CASR Mutation	28
A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis	28
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease	27
Paroxysmal Kinesigenic Dyskinesia Secondary to Brain Calcification with a Homozygous MYORG Mutation	27
A Novel SPAST Mutation Results in Spastin Accumulation and Defects in Microtubule Dynamics	27
Defining the Importance of Minor Hallucinations in Parkinson's Disease	27
Unusual Age‐Dependent Behavior of Leukocytes Telomere Length in Friedreich's Ataxia	27
Whole‐Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy	27
Pain in Multiple System Atrophy: A Community‐Based Survey	26
Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”	26
Reply to: “Early Onset Nonprogressive Generalized Dystonia Is Caused by Biallelic SHQ1 Variants”	26
Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure	26
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration	26
Movement Disorders: Volume 40, Number 3, March 2025	26
Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease	26
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release	26
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?	25
Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease	25
Issue Information	25
Static Posture Instability as a Sensitive Biomarker for Motor Abnormalities in Pre‐ataxic Spinocerebellar Ataxia Type 3 Patients	25
Movement Disorders: Volume 38, Number 12, December 2023	25
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid	25
Keyword Index	25
¹⁸F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies	25
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial	25
In Memoriam Gregor K. Wenning (1964–2024)	24
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease	24
September Infographic	24
Waveform‐Based Analysis of Head Tremor Using a Marker‐Less Tracking Algorithm with 2D‐Video: Evaluation of Sinusoidality and Rhythmicity	24
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study	24
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease	24
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings	24
Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease	24
Phenotypical Differentiation of Tremor Using Time Series Feature Extraction and Machine Learning	24
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review	24
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease	24
GAA ‐ FGF14 Expansions and	24
Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B	24
Automated Motor Tic Detection: A Machine Learning Approach	24
Learning to Have a Long‐Duration Response	23
Two London Memorials to “James Parkinson [1755–1824], Esq. Surgeon, Late of Hoxton‐Square”	23
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease	23
Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease	23
	23
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease	23
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts	23
February Infographic	23
Patient‐Derived Neurons Exhibit α‐Synuclein Pathology and Previously Unrecognized Major Histocompatibility Complex Class I Elevation in Mitochondrial Membrane Protein–Associated Neurodegene	23
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?	23
Obituary for Professor Hiroshi Shibasaki	22
Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation	22

Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers	22
Issue Information	22
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels	22
Where Do Parkinson's Disease Patients Look While Walking?	21
Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations	21
First Evidence for Disease‐Modifying Treatment of SLC20A2‐Related Primary Familial Brain Calcification	21
Movement Disorders: Volume 39, Number 9, September 2024	21
Movement Disorders: Volume 38, Number 9, September 2023	21
Proteomic Profiling in Dystonia: The Next Frontier for Pathophysiology Research and Biomarker Exploration	21
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both?	21
Investigating the Brain Mechanisms of Externally Cued Sit‐to‐Stand Movement in Parkinson's Disease	21
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial	21
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study	21
Expanding the Allelic and Clinical Heterogeneity of Movement Disorders Linked to Defects of Mitochondrial Adenosine Triphosphate Synthase	21
Reply to: “Refutation of the αSyn‐SAA‐Based Staging for Parkinson's Progression (Neuronal α‐Synuclein Disease‐Integrated Staging System [NSD‐ISS])”	21
Reply to: Enhancing Clarity in Tremor Network Gene Expression Analysis	21
Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication‐Refractory Parkinson's Disease Tremor	20
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease	20
	20
Reply to “Comments on ‘Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets’”	20
Long‐Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia	20
Functional Magnetic Resonance Imaging (fMRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies	20
Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome	20
Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes	20
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study	20
Reply to “Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals”	20
GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum	20
Pathophysiological Role of Primary Motor Cortex in Essential Tremor	19
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review	19
	19
Deep Brain Stimulation Improves Parkinson's Disease‐Associated Pain by Decreasing Spinal Nociception	19
April Infographic	19
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease	19
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut	19
	19
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R1	19
Mutation Screening of TFG in α‐Synucleinopathy and Amyotrophic Lateral Sclerosis	19
Issue Information	19
Prasinezumab: A Bayesian Perspective on Its Efficacy	19
Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's Disease	19
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?	19
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell‐Derived A9 Dopaminergic Neurons	19
Movement Disorders: Volume 38, Number 11, November 2023	19
Keyword Index	19
A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET	19
Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease	18
Catatonia: What Else Matters?	18
Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease	18
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study	18
The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia	18
Brain Imaging Phenotypes Associated with Polygenic Risk for Essential Tremor	18
Automated Quantification of Eye Tics Using Computer Vision and Deep Learning Techniques	18
Atypical and Other Parkinsonisms	18
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients	18
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study	18
March Infographic	18
Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome	18
Step Width Haptic Feedback for Gait Stability in Spinocerebellar Ataxia: Preliminary Results	18
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof‐of‐Principle Issues from a Randomized Controlled Study	18
Sympathetic Shift and Insular Alteration: Unravelling the Link Between Anxiety and Heart Rate Variability in Parkinson's Disease	18
Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial	17
Disentangling the Connection Between Neurodevelopment and Neurodegeneration in Huntington's Disease	17
Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria	17
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	17
High Pesticide Exposure Events and Dream‐Enacting Behaviors Among US Farmers	17
Globus Pallidus Internus (GPi) Neuromodulation is Not Effective in Unverricht–Lundborg Disease to Control Myoclonia	17
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis	17
Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD	17
Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus	17
Redefining Bradykinesia	17
Comments on: “Biallelic ELOVL1 Variants Are Linked to Hypomyelinating Leukodystrophy, Movement Disorder, and Ichthyosis”	17
Viewpoint on Milestones for Fellowship Training in Movement Disorders	17
The CM‐aGPi Network in the Generation of Tics in Tourette Syndrome	17
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance–Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study	17
Motor Cortical Network Excitability in Parkinson's Disease	17
Impaired Glymphatic Clearance, Measured Using Diffusion Tensor Image Analysis Along the Perivascular Space (DTI‐ALPS), is Linked to Poor Cognitive Outcomes in Parkinson's Disease	17
Spatial Metabolic Covariance Networks in Progressive Supranuclear Palsy: Implications for Symptomatology and Their Neural Basis	17
Surgery Imaging and Technology	16
Movement Disorders: Volume 40, Number 7, July 2025	16
Further Directions in Mindfulness‐Based Interventions for Tic Disorders	16
Cross‐Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease	16
Shaking Up Ataxia: FGF14 and RFC1 Repeat Expansions in Affected and Unaffected Members of a Chilean Family	16
Clinical Utility of Neurophysiologic Classification (and Declassification) of Myoclonus	16
Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease	16
Advancing Parkinson's Research: Considerations and Future Directions	16
Genetic Analysis of GCA Repeats in the GLS Gene: Implications for Undiagnosed Ataxia and Spinocerebellar Ataxia 3 in Mainland China	16
Bilateral Simultaneous Magnetic Resonance–Guided Focused Ultrasound Pallidotomy for Life‐Threatening Status Dystonicus	16
Diffusion Magnetic Resonance Imaging Microstructural Abnormalities in Multiple System Atrophy: A Comprehensive Review	16
Dysautonomia Is Associated with Cognitive Fluctuation in Dementia with Lewy Bodies	16
Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”	16
Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism	15
Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease	15
Issue Information	15
Top Movement Disorders Journal Reviewers from 2024	15
A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease	15